ICI in Early TNBC

CE / CME

Immune Checkpoint Inhibition in Early-Stage TNBC

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Nurses: 0.50 Nursing contact hour

Released: September 15, 2022

Expiration: September 14, 2023

Denise A. Yardley
Denise A. Yardley, MD

Activity

Progress
1
Course Completed
If you are a practicing healthcare professional, how many patients with breast cancer do you provide care for in a typical month?

Which of the following most accurately describes which patients with high-risk, early-stage TNBC are candidates for neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab based on available data from the KEYNOTE-522 trial and the current indication in this disease setting?

In this module, Denise A. Yardley, MD, reviews and discusses recent advances in neo/adjuvant immune checkpoint inhibition for early-stage triple-negative breast cancer (TNBC).

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Several questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.